#obesity

Aspirin helped reduce liver fat in people with metabolic dysfunction-associated steatotic liver disease, or MASLD.

NAFLD is associated with risk factors such as obesity and inflammatory biomarkers and with events including heart attacks and strokes.

In a mice study, daily consumption of pecans helped reduce inflammation and increase energy expenditure.

Lean people had a higher mortality rate despite experiencing fewer metabolic problems.

Obesity-linked liver disease has increased 131% in the past three decades.

The findings could potentially lead to the first FDA approval of a treatment for fatty liver disease.

The risk for cardiovascular events and all-cause mortality were greatly reduced in people with obesity and fatty liver disease.

Seafood, seaweed and soy products were among the foods that helped slow the progression of liver fibrosis.

Competition to claim a market has triggered a wave of advertising that has provoked the concern of regulators and doctors worldwide.

People who ate more fast food, as well as those with diabetes or obesity, had a higher risk for NAFLD.

Research confirms exercise as effective treatment for fatty liver disease.

BMI may not be the best way to assess health risks linked to excess weight.

Most outcomes were similar in lean and heavy people with fatty liver disease, but the lean group had higher liver-related mortality.

Some 20% of those with NAFLD also showed signs of liver fibrosis.

Among people with fatty liver disease, those with diabetes were more likely to advance by one fibrosis stage in less than six years.

Positive results announced by Madrigal Pharmaceuticals could potentially lead to the first drug approval for fatty liver disease.